Destiny Pharma plc – XF-73 Phase 2b data to be presented at ECCMID

Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress

  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 9th July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of XF-73 nasal gel will be presented at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on Saturday, 10 July at 7:35 pm CET

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH